Osteonecrosis of the Femoral Head in Korean Patients with Human Immunodeficiency Virus Infection
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Osteonecrosis of the femoral head (ONFH) is a disabling condition that often necessitates total hip arthroplasty (THA). Although ONFH occurs more frequently among patients with human immunodeficiency virus (HIV) than among the general population, there is little epidemiological information regarding ONFH in Korean patients with HIV. In the present study, we aimed to investigate the incidence and clinical features of ONFH among Korean patients with HIV. Materials and Methods: In this retrospective study, we reviewed the medical records of 1,250 Korean patients with HIV treated from January 1990 to December 2019. A standardised data collection sheet was used to obtain clinical information. Imaging data were analysed by a radiologist in accordance with the 2019 revised version of the Association Research Circulation Osseous (ARCO) staging system for ONFH. Results: Among the 1,250 included patients, 13 patients (1.04%; 3 women, 10 men) were diagnosed with ONFH. The overall incidence of ONFH was 1.29 per 1,000 person-years (PYs) (95% confidence interval [CI]: 0.7 – 2.4 per 1,000 PYs). Median age among the 13 patients with ONFH was 47 years (interquartile range [IQR]: 41 – 57 years). The median duration since HIV diagnosis was 4.8 years (IQR: 2.3 – 10.1 years). The median CD4 cell count at the time of ONFH diagnosis was 381 cells/ mm3 (IQR: 161 – 551 cells/mm3 ). At the initial diagnosis of ONFH, 83.3% of patients exhibited bilateral involvement. ARCO stage 3 or 4 osteonecrosis was observed in 83% of patients. Among 22 hips, stage 1 ONFH was noted in 2 (9.1%), stage 2 ONFH was noted in 7 (31.8%), stage 3 ONFH was noted in 9 (40.9%), and stage 4 ONFH was noted in 4 (18.2%). THA was eventually performed in 84.6% of patients. Five (38.5%) patients had a history of steroid use, 4 (30.8%) patients had a history of alcohol abuse and 10 (76.9%) were smokers. Eight (61.5%) patients had a history of acquired immune deficiency syndrome-defining illness, including 7 with tuberculosis and 1 with pneumocystis pneumonia. Nine patients (69.2%) had a nadir CD4 cell count <200/µL, and 3 (23.1%) had a history of bone fracture. Overall, 84% of patients were exposed to antiretroviral therapy, while 54% had taken protease inhibitors for more than 1 year. Conclusion: Considering that relatively high incidence of ONFH in patients with HIV, a high index of suspicion for those with risk factors and those with groin or hip pain for is required in HIV-infected patients.
Abstract
Background: Osteonecrosis of the femoral head (ONFH) is a disabling condition that often necessitates total hip arthroplasty (THA). Although ONFH occurs more frequently among patients with human immunodeficiency virus (HIV) than among the general population, there is little epidemiological information regarding ONFH in Korean patients with HIV. In the present study, we aimed to investigate the incidence and clinical features of ONFH among Korean patients with HIV. Materials and Methods: In this retrospective study, we reviewed the medical records of 1,250 Korean patients with HIV treated from January 1990 to December 2019. A standardised data collection sheet was used to obtain clinical information. Imaging data were analysed by a radiologist in accordance with the 2019 revised version of the Association Research Circulation Osseous (ARCO) staging system for ONFH. Results: Among the 1,250 included patients, 13 patients (1.04%; 3 women, 10 men) were diagnosed with ONFH. The overall incidence of ONFH was 1.29 per 1,000 person-years (PYs) (95% confidence interval [CI]: 0.7 – 2.4 per 1,000 PYs). Median age among the 13 patients with ONFH was 47 years (interquartile range [IQR]: 41 – 57 years). The median duration since HIV diagnosis was 4.8 years (IQR: 2.3 – 10.1 years). The median CD4 cell count at the time of ONFH diagnosis was 381 cells/ mm3 (IQR: 161 – 551 cells/mm3 ). At the initial diagnosis of ONFH, 83.3% of patients exhibited bilateral involvement. ARCO stage 3 or 4 osteonecrosis was observed in 83% of patients. Among 22 hips, stage 1 ONFH was noted in 2 (9.1%), stage 2 ONFH was noted in 7 (31.8%), stage 3 ONFH was noted in 9 (40.9%), and stage 4 ONFH was noted in 4 (18.2%). THA was eventually performed in 84.6% of patients. Five (38.5%) patients had a history of steroid use, 4 (30.8%) patients had a history of alcohol abuse and 10 (76.9%) were smokers. Eight (61.5%) patients had a history of acquired immune deficiency syndrome-defining illness, including 7 with tuberculosis and 1 with pneumocystis pneumonia. Nine patients (69.2%) had a nadir CD4 cell count <200/µL, and 3 (23.1%) had a history of bone fracture. Overall, 84% of patients were exposed to antiretroviral therapy, while 54% had taken protease inhibitors for more than 1 year. Conclusion: Considering that relatively high incidence of ONFH in patients with HIV, a high index of suspicion for those with risk factors and those with groin or hip pain for is required in HIV-infected patients.
참고문헌 (22)
- Yoon BH, "The 2019 revised version of association research circulation osseous staging", J Arthroplasty, 35, pp.933~940 (2020)
- Lamb JN, "Avascular necrosis of the hip", BMJ, 365, pp.l2178~ (2019)
- Morse CG, "The incidence and natural history of osteonecrosis in HIV-infected adults", Clin Infect Dis, 44, pp.739~748 (2007)
- Permpalung N, "Protease inhibitors and avascular necrosis : a systematic review and meta-analysis", Int J Antimicrob Agents, 44, pp.93~95 (2014)
- Mary-Krause M, "Risk factors for osteonecrosis in HIV-infected patients : impact of treatment with combination antiretroviral therapy", AIDS, 20, pp.1627~1635 (2006)
- Scribner AN, "Osteonecrosis in HIV : a case-control study", J Acquir Immune Defic Syndr, 25, pp.19~25 (2000)
- Zhao DW, "Prevalence of nontraumatic osteonecrosis of the femoral head and its associated", Chin Med J(Engl), 128, pp.2843~2850 (2015)
- Miller KD, "High prevalence of osteonecrosis of the femoral head in HIV-infected adults", Ann Intern Med, 137, pp.17~25 (2002)
- Kang JS, "Prevalence of osteonecrosis of the femoral head : a nationwide epidemiologic analysis in Korea", J Arthroplasty, 24, pp.1178~1183 (2009)
- 박진용, "HIV 감염 환자에서 발생한 대퇴골두 무혈성괴사: 증례보고 및 문 헌고찰", Infection and Chemotherapy, 44(6), pp.508~511 (2012), 대한감염학회
- Lucas GM, "Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic", AIDS, 16, pp.767~774 (2002)
- Gardeniers J, "ARCO committee on terminology and staging. A new proposition of terminology and an international classification of osteonecrosis", ARCO Newsl, 3, pp.153~159 (1991)
- Keruly JC, "Increasing incidence of avascular necrosis of the hip in HIV-infected patients", J Acquir Immune Defic Syndr, 28, pp.101~102 (2001)
- Ho YC, "Osteonecrosis in patients with human immunodeficiency virus type 1 infection in Taiwan", Jpn J Infect Dis, 60, pp.382~386 (2007)
- Hasse B, "Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study : a nested case-control study", AIDS Res Hum Retroviruses, 20, pp.909~915 (2004)
- Gutiérrez F, "Osteonecrosis in patients infected with HIV : clinical epidemiology and natural history in a large case series from Spain", J Acquir Immune Defic Syndr, 42, pp.286~292 (2006)
- Borges ÁH, "Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort", Clin Infect Dis, 64, pp.1413~1421 (2017)
- Yombi JC, "Osteonecrosis of the femoral head in patients with type 1 human immunodeficiency virus infection : clinical analysis and review", Clin Rheumatol, 28, pp.815~823 (2009)
- Glesby MJ, "Osteonecrosis in patients infected with human immunodeficiency virus : a case-control study", J Infect Dis, 184, pp.519~523 (2001)
- Newman MD, "Bone disorders, hypertension, and mitochondrial toxicity in HIV disease", Top HIV Med, 11, pp.10~15 (2003)
- Choi HR, "Osteonecrosis of the femoral head : diagnosis and classification systems", Curr Rev Musculoskelet Med, 8, pp.210~220 (2015)
- Boontanapibul K, "Diagnosis of osteonecrosis of the femoral head : Too little, too late, and independent of etiology", J Arthroplasty, 35, pp.2342~2349 (2020)